STOCK TITAN

Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Biohaven Ltd. entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, establishing an “at-the-market” equity offering program. From May 4, 2026, the company may sell up to an aggregate offering price of $350.0 million in common shares through J.P. Morgan as manager.

Shares may be sold on the New York Stock Exchange or via other negotiated transactions at prevailing market prices, with actual sales determined over time by the company’s capital needs and market conditions. The program is issued under an effective shelf registration statement and related base prospectus and prospectus supplement filed on May 4, 2026.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
ATM program size $350.0 million aggregate offering price Common shares under Equity Distribution Agreement from May 4, 2026
Registration statement file number File No. 333-295531 Shelf registration statement filed May 4, 2026
Equity Distribution Agreement amendment date May 4, 2026 Amendment No. 2 with J.P. Morgan Securities LLC
Equity Distribution Agreement financial
"entered into Amendment No. 2 (“Amendment No. 2”) to the Equity Distribution Agreement, dated October 2, 2023"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at-the-market financial
"in an “at-the-market” equity offering program through the Manager"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
shelf registration statement regulatory
"offered and sold pursuant to an effective shelf registration statement (the “Registration Statement”)"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"and a prospectus supplement, dated May 4, 2026, filed with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification rights financial
"The Equity Distribution Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations"
Inline XBRL technical
"104 | The cover page of this on formatted as Inline XBRL."
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Offering Type ATM
0001935979false00019359792026-05-052026-05-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2026
Biohaven Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands001-41477Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 8.01Other Events.
On May 4, 2026, Biohaven Ltd. (the “Company”) entered into Amendment No. 2 (“Amendment No. 2”) to the Equity Distribution Agreement, dated October 2, 2023 (the “Original Equity Distribution Agreement”), as previously amended by Amendment No. 1, dated August 16, 2024 (“Amendment No. 1” and, together with the Original Equity Distribution Agreement and Amendment No. 2, the “Equity Distribution Agreement”), with J.P. Morgan Securities LLC, as manager (the “Manager”), pursuant to which the Company may sell, from time to time, from and after May 4, 2026, up to an aggregate offering price of $350.0 million of its common shares, without par value (the “Common Shares”), in an “at-the-market” equity offering program through the Manager. Sales of the Common Shares made pursuant to the Equity Distribution Agreement, if any, may be made by means of ordinary brokers’ transactions on the New York Stock Exchange or otherwise at market prices prevailing at the time of sale or negotiated transactions, or as otherwise agreed with the Manager. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Common Shares, capital needs and determinations by the Company of the appropriate sources of funding for the Company.
The Equity Distribution Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties and termination provisions.
The $350.0 million aggregate offering price of Common Shares will be offered and sold pursuant to an effective shelf registration statement (the “Registration Statement”) filed with the Securities and Exchange Commission on May 4, 2026 (File No. 333-295531), a base prospectus, dated May 4, 2026, included as part of the Registration Statement and a prospectus supplement, dated May 4, 2026, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.
The foregoing description of the Equity Distribution Agreement is not complete and is qualified in its entirety by reference to the full text of the Original Equity Distribution Agreement, Amendment No. 1 and Amendment No. 2, which are Exhibits 1.1, 1.2 and 1.3, respectively, to this Current Report on Form 8-K and are incorporated by reference into this Item 8.01. A copy of the opinion of Maples & Calder relating to the issuance of the Common Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K. Exhibits 1.1, 1.2, 1.3, 5.1 and 23.1 hereto are hereby incorporated by reference into the Registration Statement.
This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2


Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Exhibit Description
1.1
Equity Distribution Agreement, dated October 2, 2023, by and between Biohaven Ltd. and J.P. Morgan Securities LLC (incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K filed on October 3, 2023).
1.2
Amendment No. 1 to the Equity Distribution Agreement, dated August 16, 2024, by and between Biohaven Ltd. and J.P. Morgan Securities LLC (incorporated by reference to Exhibit 1.2 to the Company’s Current Report on Form 8-K (Accession No. 0001628280-24-037568) filed on August 16, 2024).
1.3
Amendment No. 2 to the Equity Distribution Agreement, dated May 4, 2026, by and between Biohaven Ltd. and J.P. Morgan Securities LLC.
5.1
Opinion of Maples & Calder.
23.1
Consent of Maples & Calder (included in Exhibit 5.1).
104
The cover page of this Current Report on Form 8-K formatted as Inline XBRL.
3


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 5, 2026
Biohaven Ltd.
By:
/s/ Vlad Coric
Vlad Coric, M.D.
Chief Executive Officer
4

FAQ

What did Biohaven (BHVN) announce in this 8-K filing?

Biohaven entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, creating an at-the-market program to sell up to $350.0 million of common shares under an effective shelf registration statement and related prospectus documents.

How large is Biohaven’s new at-the-market offering program?

The at-the-market program allows Biohaven to sell common shares with an aggregate offering price of up to $350.0 million. These shares may be issued over time, giving the company flexibility to access equity capital as conditions and funding needs evolve.

How will Biohaven’s common shares be sold under this program?

Common shares may be sold through J.P. Morgan Securities LLC by ordinary brokers’ transactions on the New York Stock Exchange, at prevailing market prices, or through negotiated transactions or other methods agreed with the manager, providing multiple avenues for potential share sales.

Under what regulatory framework is Biohaven’s $350.0 million program issued?

The $350.0 million aggregate offering price of common shares will be offered and sold under an effective shelf registration statement filed on May 4, 2026, together with a base prospectus and a prospectus supplement filed pursuant to Rule 424(b) under the Securities Act of 1933.

Who is managing Biohaven’s at-the-market equity offering?

J.P. Morgan Securities LLC is acting as the manager under the Equity Distribution Agreement. It will facilitate sales of Biohaven’s common shares in the at-the-market program using exchange trades, negotiated transactions, or other agreed methods, subject to customary conditions and provisions.

Does this filing itself offer Biohaven (BHVN) shares for sale?

The document explicitly states it does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction where such actions would be unlawful. Actual offers and sales occur under the effective registration statement, base prospectus, and prospectus supplement referenced.

Filing Exhibits & Attachments

5 documents